4967
KOBAYASHI PHARMACEUTICAL CO.,LTD.
小林製薬株式会社
Consumer Defensive · Household & Personal Products
Kobayashi Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells OTC pharmaceuticals, guasi-drugs, deodorizing air fresheners, and sanitary products in Japan, the United States, Southeast Asia, and internationally. The company offers Ammeltz, an anti-inflammatory pain relief medicine; Dent, an effervescent denture cleaning agent; Ekitai Bluelet Okudake, a toilet bowl cleaner; Naicitol, a Chinese herbal medicine that promotes the breakdown and metabolism of fat; BreathCare, an oral breath freshener capsule; Netsusama sheet, a cooling gel sheet; and deodorizing air fresheners, lens cleaners, and oral hygiene products. It also manufactures and sells pharmaceuticals, fragrances, deodorants, cosmetics, health food, synthetic resin processed products, paper products, and hand warmers; and sells daily necessities. In addition, the company engages in transportation, real estate management, advertising planning and production, sales promotion and market research, promotional goods production and sales, and asset management activities, as well as in pharmacy, retail, and cleaning industries. Kobayashi Pharmaceutical Co., Ltd. was founded in 1886 and is headquartered in Osaka, Japan.
Price
¥5,852
Market Cap
¥435.0B
Ent. Value
—
Net Cash
est
—
Shares Out.
74.3M
P / E
119.0×
EV / EBIT
—
P / Book
2.07×
P / NCAV
5.15×
Div. Yield
1.78%
Financials
| Metric |
FY 2025
EDINET ↗ |
FY 2024
EDINET ↗ |
FY 2023
EDINET ↗ |
FY 2022
EDINET ↗ |
FY 2021
EDINET ↗ |
|---|---|---|---|---|---|
| Net Sales | ¥165.7B | ¥165.6B | ¥173.5B | ¥166.3B | ¥155.3B |
| Cost of Sales | ¥81.0B | ¥78.0B | ¥77.1B | ¥73.9B | ¥66.5B |
| Gross Profit | ¥84.7B | ¥87.6B | ¥96.4B | ¥92.3B | ¥88.8B |
| SG&A | ¥69.8B | ¥62.7B | ¥70.6B | ¥65.7B | ¥62.7B |
| Operating Income | ¥14.9B | ¥24.9B | ¥25.8B | ¥26.7B | ¥26.1B |
| Non-Operating Income | ¥2.5B | ¥2.5B | ¥2.2B | ¥2.0B | ¥2.4B |
| Dividend Income | ¥664M | ¥608M | ¥548M | ¥493M | ¥457M |
| Interest Income | ¥335M | ¥207M | ¥214M | ¥85M | ¥131M |
| Non-Operating Expenses | ¥402M | ¥476M | ¥637M | ¥399M | ¥441M |
| Interest Expense | ¥28M | ¥28M | ¥29M | ¥18M | ¥18M |
| Ordinary Income | ¥17.0B | ¥26.9B | ¥27.3B | ¥28.3B | ¥28.0B |
| Pre-tax Income | ¥3.7B | ¥13.9B | ¥27.6B | ¥27.9B | ¥27.6B |
| Income Taxes | ¥83M | ¥3.8B | ¥7.2B | ¥7.9B | ¥7.9B |
| Current Tax | ¥4.4B | ¥5.2B | ¥8.3B | ¥8.3B | ¥7.9B |
| Deferred Tax | ¥-4.3B | ¥-1.4B | ¥-1.1B | ¥-332M | ¥-2M |
| Net Income (owners) | ¥3.7B | ¥10.1B | ¥20.3B | ¥20.0B | ¥19.7B |
| Minority Interest | ¥4M | ¥4M | — | — | — |
| Comprehensive Income | ¥5.1B | ¥15.9B | ¥26.0B | ¥22.8B | ¥23.2B |
| EBITDA | ¥23.7B | ¥32.9B | ¥31.8B | ¥32.0B | ¥30.9B |
| Goodwill Amort. (J-GAAP) | ¥1.4B | ¥1.4B | ¥1.1B | ¥998M | ¥862M |
| EPS | ¥49.19 | ¥135.42 | ¥268.16 | ¥259.63 | ¥252.36 |
| Shares Outstanding | 74.3M | 74.3M | 74.3M | 76.0M | 77.7M |
| Shares Issued (total) | 78.0M | 78.0M | 78.0M | 78.0M | 82.0M |
| Treasury Shares | 3.7M | 3.7M | 3.7M | 2.0M | 4.3M |
| Metric |
FY 2025
EDINET ↗ |
FY 2024
EDINET ↗ |
FY 2023
EDINET ↗ |
FY 2022
EDINET ↗ |
FY 2021
EDINET ↗ |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | ¥275.3B | ¥265.4B | ¥267.5B | ¥255.8B | ¥252.6B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Current Assets | ¥148.8B | ¥144.5B | ¥158.3B | ¥172.9B | ¥181.9B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash & Deposits | ¥62.3B | ¥50.9B | ¥71.5B | ¥96.2B | ¥95.0B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Non-Current Assets | ¥126.5B | ¥120.9B | ¥109.1B | ¥82.9B | ¥70.7B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| PP&E | ¥67.4B | ¥67.4B | ¥47.7B | ¥34.8B | ¥22.5B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Goodwill | ¥7.7B | ¥9.3B | ¥9.7B | ¥7.1B | ¥7.2B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Intangible Assets | ¥17.4B | ¥20.7B | ¥21.6B | ¥13.3B | ¥12.7B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investment Securities | ¥31.8B | ¥24.6B | ¥32.1B | ¥28.5B | ¥29.5B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Deferred Tax Assets | ¥5.3B | ¥3.1B | ¥2.6B | ¥1.8B | ¥1.5B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Liabilities | ¥64.3B | ¥51.9B | ¥62.7B | ¥57.9B | ¥57.0B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Current Liabilities | ¥60.1B | ¥46.4B | ¥56.1B | ¥51.8B | ¥50.7B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Accounts Payable | ¥8.5B | ¥8.3B | ¥8.7B | ¥9.1B | ¥9.3B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ST Debt | — | — | — | — | ¥1M | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Taxes Payable | ¥1.9B | ¥1.9B | ¥4.1B | ¥4.0B | ¥3.8B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Non-Current Liabilities | ¥4.2B | ¥5.5B | ¥6.5B | ¥6.1B | ¥6.2B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pension Obligations | ¥989M | ¥1.0B | ¥939M | ¥2.0B | ¥2.0B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Deferred Tax Liab. | — | ¥1.6B | ¥2.6B | ¥1.3B | ¥1.6B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Equity | ¥211.0B | ¥213.5B | ¥204.8B | ¥197.9B | ¥195.6B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Capital Stock | ¥3.5B | ¥3.5B | ¥3.5B | ¥3.5B | ¥3.5B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Capital Surplus | ¥522M | ¥522M | ¥522M | ¥522M | ¥4.2B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Retained Earnings | ¥204.2B | ¥208.2B | ¥205.7B | ¥194.3B | ¥200.5B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treasury Stock | ¥-24.8B | ¥-24.8B | ¥-24.8B | ¥-14.5B | ¥-23.7B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| AOCI | ¥26.8B | ¥25.3B | ¥19.5B | ¥13.9B | ¥11.1B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity (owners) | ¥183.4B | ¥187.4B | ¥184.9B | ¥183.8B | ¥184.5B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Minority Interests | ¥9M | ¥4M | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Interest-Bearing Debt ⓘ | — | — | — | — | ¥1M | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net Cash ⓘ | ¥62.3B | ¥50.9B | ¥71.5B | ¥96.2B | ¥95.0B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| NCAV ⓘ | ¥84.5B | ¥92.6B | ¥95.7B | ¥115.0B | ¥124.9B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| NCAV/Share | ¥1,137 | ¥1,245 | ¥1,287 | ¥1,512 | ¥1,607 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| BV/Share | ¥2,468 | ¥2,521 | ¥2,487 | ¥2,418 | ¥2,373 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Metric |
FY 2025
EDINET ↗ |
FY 2024
EDINET ↗ |
FY 2023
EDINET ↗ |
FY 2022
EDINET ↗ |
FY 2021
EDINET ↗ |
|---|---|---|---|---|---|
| Operating CF | ¥25.6B | ¥11.2B | ¥18.4B | ¥31.9B | ¥22.4B |
| Interest Paid | ¥-28M | ¥-34M | ¥-22M | ¥-18M | ¥-17M |
| Interest Received | ¥929M | ¥801M | ¥754M | ¥572M | ¥654M |
| D&A | ¥7.4B | ¥6.6B | ¥4.9B | ¥4.4B | ¥4.0B |
| Goodwill Amort. | ¥1.4B | ¥1.4B | ¥1.1B | ¥998M | ¥862M |
| Investing CF | ¥-154M | ¥-18.4B | ¥-19.6B | ¥-14.3B | ¥8.0B |
| CapEx | ¥13.3B | ¥26.1B | ¥12.8B | ¥14.7B | ¥3.7B |
| Purchase Investments | ¥-6.6B | ¥-18M | ¥-220M | ¥-19M | ¥-182M |
| Proceeds from Invest. | ¥3.5B | ¥959M | ¥531M | ¥45M | ¥402M |
| Financing CF | ¥-7.9B | ¥-7.8B | ¥-19.5B | ¥-20.8B | ¥-10.4B |
| Dividends Paid | ¥-7.7B | ¥-7.5B | ¥-7.2B | ¥-6.5B | ¥-6.3B |
| Share Buybacks | — | ¥0M | ¥-12.0B | ¥-14.1B | ¥-3.9B |
| Free Cash Flow | ¥12.3B | ¥-14.8B | ¥5.6B | ¥17.2B | ¥18.8B |
| Net Change in Cash | ¥18.7B | ¥-13.7B | ¥-19.8B | ¥-2.5B | ¥20.8B |
| Metric |
FY 2025
EDINET ↗ |
FY 2024
EDINET ↗ |
FY 2023
EDINET ↗ |
FY 2022
EDINET ↗ |
FY 2021
EDINET ↗ |
|---|---|---|---|---|---|
| ROE | 1.7% | 4.8% | 10.1% | 10.2% | 10.4% |
| ROA | 1.4% | 3.8% | 7.8% | 7.9% | 7.8% |
| EPS | ¥49.19 | ¥135.42 | ¥268.16 | ¥259.63 | ¥252.36 |
| DPS | ¥104.00 | ¥102.00 | ¥101.00 | ¥90.00 | ¥83.00 |
| BPS | ¥2,827.68 | ¥2,862.28 | ¥2,749.17 | ¥2,600.04 | ¥2,515.53 |
| FCF/Share | ¥166 | ¥-199 | ¥75 | ¥226 | ¥241 |
| NCAV/Share | ¥1,137 | ¥1,245 | ¥1,287 | ¥1,512 | ¥1,607 |
| Payout Ratio | 211.4% | 75.3% | 37.7% | 34.7% | 32.9% |
Event Timeline
S Shareholder
A Capital Signal
Large Shareholder Reports 6
| # | Shareholder | Shares (thou.) | % of Total |
|---|---|---|---|
| 1 | 小林 章浩 | 9,264 | 12.46% |
| 2 | (公財)小林財団 | 6,000 | 8.07% |
| 3 |
The Master Trust Bank of Japan, Ltd. (Trust Account)
日本マスタートラスト信託銀行㈱（信託口）
|
5,246 | 7.06% |
| 4 | オアシスジャパンストラテジックファンド （常任代理人ゴールドマン・サックス証券㈱） | 3,855 | 5.19% |
| 5 | 渡部 育子 | 2,325 | 3.13% |
| 6 | ㈱フォーラム | 2,071 | 2.79% |
| 7 | オアシスジャパンストラテジックファンドＹ （常任代理人シティバンク、エヌ・エイ東京支店） | 2,039 | 2.74% |
| 8 | オアシスインベストメントⅡマスターファンド （常任代理人ゴールドマン・サックス証券㈱） | 1,946 | 2.62% |
| 9 | 井植 由佳子 | 1,863 | 2.51% |
| 10 | ㈱慧光 | 1,700 | 2.29% |
as of 2025-12-31
Source: EDINET ↗
Ownership by year — hover bars for detail
Domestic Nominees
7.1%
-2.4% vs 2024
Trust bank custodians — GPIF, pensions, investment trusts
Foreign Custodians
0.0%
+0.0% vs 2024
Sub-custodians for foreign asset managers
Direct / Strategic
41.8%
+0.0% vs 2024
Named entities with disclosed investment intent
Bar = % of shares outstanding · top-10 covers 48.9% · grey = other shareholders · 2025
| Shareholder | Trend | 2023 | 2024 Activist | 2025 Activist |
|---|---|---|---|---|
| 小林 章浩 | 12.46% | 12.46% | 12.46% | |
| Oasis Management Activist | — | 10.55% | 10.55% | |
| 小林財団 | 8.07% | 8.07% | 8.07% | |
| 日本マスタートラスト信託銀行 | 11.21% | 9.42% | 7.06% -2.36% | |
| 渡部 育子 | 3.13% | 3.13% | 3.13% | |
| ㈱フォーラム | 2.79% | 2.79% | 2.79% | |
| 井植 由佳子 | 2.51% | 2.51% | 2.51% | |
| ㈱慧光 | 2.29% | 2.29% | 2.29% | |
| 宮田 彰久 last seen 2023 | Exited Top 10 | 2.07% | — | — |
| 小林製薬取引先持株会 last seen 2023 | Exited Top 10 | 1.99% | — | — |
| 日本カストディ銀行 last seen 2023 | Exited Top 10 | 3.89% | — | — |
| Concentration (HHI) ⓘ | 399 | 450 | 411 |
3 fiscal years · top-10 holders per year · >2,500 HHI = high concentration · entity-resolved
Portfolio Book Value
¥11,217M
-1% since 2023
Holdings
49
+1 new
9 exited
Trend
1 unwinding
vs 2023
| Held Company | FY2025 ¥11,217M total | FY2023 ¥11,360M total | |||
|---|---|---|---|---|---|
| Book Val ¥M | Shares | Book Val ¥M | Shares | ||
|
MatsukiyoCocokara & Co
㈱マツキヨココカラ＆カンパニー
|
3,446 |
1,270,908
|
3,173 | 1,270,908 | M |
|
PALTAC CORPORATION
㈱ＰＡＬＴＡＣ
|
2,894 |
600,000
|
2,678 | 600,000 | M |
|
TOHO HOLDINGS CO.,LTD.
東邦ホールディングス㈱
|
870 |
186,500
|
600 | 186,500 | M |
|
Dai Nippon Printing Co.,Ltd.
大日本印刷㈱
|
856 |
+100.0%
↑
318,000
|
663 | 159,000 | M |
|
HAKUHODO DY HOLDINGS INCORPORATED
㈱博報堂ＤＹホールディングス
|
698 |
598,700
|
646 | 598,700 | M |
|
MANDOM CORPORATION
㈱マンダム
|
662 |
-29.6%
↓
243,700
|
441 | 346,000 | M |
|
SUNDRUG CO.,LTD.
㈱サンドラッグ
|
394 |
+5.6%
↑
91,549
|
392 | 86,698 | |
|
螟ｧ譛ｨ繝倥Ν繧ｹ繧ｱ繧｢繝帙�ｼ繝ｫ繝�繧｣繝ｳ繧ｰ繧ｹ譬ｪ蠑丈ｼ夂､ｾ
大木ヘルスケアホールディングス㈱
|
298 |
+4.0%
↑
209,758
|
217 | 201,673 | M |
|
ARATA CORPORATION
㈱あらた
|
281 |
91,430
|
284 | 91,430 | M |
|
PLANET,INC.
㈱プラネット
|
223 |
176,000
|
215 | 176,000 | |
|
AEON Co.,Ltd.
イオン㈱
|
174 |
+201.7%
↑
70,515
|
73 | 23,375 | |
|
SUGI HOLDINGS CO.,LTD.
スギホールディングス㈱
|
60 |
+200.0%
↑
16,368
|
35 | 5,456 | |
|
TSURUHA HOLDINGS INC.
㈱ツルハホールディングス
|
57 |
+400.0%
↑
20,000
|
51 | 4,000 | |
|
LIFE CORPORATION
㈱ライフコーポレーション
|
56 |
+115.3%
↑
21,943
|
33 | 10,193 | |
|
CREATE SD HOLDINGS CO.,LTD
㈱クリエイトＳＤホールディングス
|
40 |
12,000
|
36 | 12,000 | |
| エイチ・ツー・オーリテイリング㈱ | 38 |
+10.2%
↑
18,667
|
25 | 16,946 | |
| UNQ Holdings Ltd． | 37 |
657,600
|
15 | 657,600 | |
|
DCM Holdings Co.,Ltd.
ＤＣＭホールディングス㈱
|
34 |
+321.3%
↑
21,065
|
6 | 5,000 | |
|
Fuso Pharmaceutical Industries,Ltd.
扶桑薬品工業㈱
|
14 |
NEW
New
6,195
|
— | ||
|
Alfresa Holdings Corporation
アルフレッサホールディングス㈱
|
13 |
5,588
|
13 | 5,588 | |
|
FUJI CO., LTD.
㈱フジ
|
12 |
6,000
|
11 | 6,000 | |
|
Harima-Kyowa Co.,LTD.
ハリマ共和物産㈱
|
12 |
6,600
|
15 | 6,600 | M |
|
OKUWA CO., LTD.
㈱オークワ
|
12 |
+15.1%
↑
14,571
|
10 | 12,655 | |
|
CAWACHI LIMITED
㈱カワチ薬品
|
12 |
4,000
|
10 | 4,000 | |
|
VALOR HOLDINGS CO.,LTD.
㈱バローホールディングス
|
10 |
3,168
|
7 | 3,168 | |
|
T&D Holdings, Inc.
㈱Ｔ＆Ｄホールディングス
|
5 |
1,600
|
3 | 1,600 | |
|
ROHTO PHARMACEUTICAL CO.,LTD.
ロート製薬㈱
|
5 |
2,000
|
5 | 2,000 | M |
|
ZERIA PHARMCEUTICAL CO., LTD.
ゼリア新薬工業㈱
|
2 |
1,100
|
2 | 1,100 | |
|
NIDEC CORPORATION
ニデック㈱
|
1 |
+100.0%
↑
800
|
2 | 400 | |
|
Lion Corporation
ライオン㈱
|
1 |
1,000
|
1 | 1,000 | |
|
Otsuka Holdings Co., Ltd.
大塚ホールディングス㈱
|
— | — | |||
|
Ajinomoto Co., Inc.
味の素㈱
|
— | — | |||
|
Kao Corporation
花王㈱
|
— | — | |||
|
KOMATSU LTD.
㈱小松製作所
|
— | — | |||
|
Earth Corporation
アース製薬㈱
|
— | — | |||
|
ASAHI GROUP HOLDINGS,LTD.
アサヒグループホールディングス㈱
|
— | — | |||
|
Takeda Pharmaceutical Company Limited
武田薬品工業㈱
|
— | — | |||
|
Eisai Co., Ltd.
エーザイ㈱
|
— | — | |||
|
HISAMITSU PHARMACEUTICAL CO.,INC.
久光製薬㈱
|
— | — | |||
|
TSUMURA & CO.
㈱ツムラ
|
— | — | |||
|
繧ｫ繝ｫ繝薙�ｼ譬ｪ蠑丈ｼ夂､ｾ
カルビー㈱
|
— | — | |||
|
KAGOME CO.,LTD.
カゴメ㈱
|
— | — | |||
|
Shiseido Company, Limited
㈱資生堂
|
— | — | |||
|
ONO PHARMACEUTICAL CO., LTD.
小野薬品工業㈱
|
— | — | |||
|
Astellas Pharma Inc.
アステラス製薬㈱
|
— | — | |||
|
SANTEN PHARMACEUTICAL CO.,LTD.
参天製薬㈱
|
— | — | |||
|
S.T.CORPORATION
エステー㈱
|
— | — | |||
|
Mitsubishi Chemical Gloup Corporation
三菱ケミカルグループ㈱
|
— | — | |||
|
TAISHO PHARMACEUTICAL HOLDINGS CO., LTD.
大正製薬ホールディングス㈱
|
— | — | |||
|
UNICHARM CORPORATION
ユニ・チャーム㈱
|
— |
−100%
Exit
—
|
1 | 300 | |
|
Mizuho Financial Group, Inc.
㈱みずほフィナンシャルグループ
|
— |
−100%
Exit
—
|
15 | 6,372 | M |
|
Sumitomo Mitsui Financial Group, Inc.
㈱三井住友フィナンシャルグループ
|
— |
−100%
Exit
—
|
96 | 14,064 | M |
|
TOPPAN Holdings Inc.
ＴＯＰＰＡＮホールディングス㈱
|
— |
−100%
Exit
—
|
905 | 230,000 | M |
|
Mitsubishi UFJ Financial Group, Inc.
㈱三菱ＵＦＪフィナンシャル・グループ
|
— |
−100%
Exit
—
|
440 | 363,860 | M |
|
Nomura Holdings Inc.
野村ホールディングス㈱
|
— |
−100%
Exit
—
|
127 | 200,000 | M |
|
CB GROUP MANAGEMENT Co., Ltd
ＣＢグループマネジメント㈱
|
— |
−100%
Exit
—
|
90 | 18,280 | |
|
ENCHO CO.,LTD.
㈱エンチョー
|
— |
−100%
Exit
—
|
17 | 17,926 | |
|
inageya co.,ltd.
㈱いなげや
|
— |
−100%
Exit
—
|
7 | 5,748 | |
| Portfolio total | 11,217 | 11,360 | |||
Book value in ¥M · ↓ reduced · ↑ increased vs prior year · M = mutual holding